PharmaCyte Biotech, Inc. (PMCB)
$0.52-$0.03 (-4.66%) Today
Latest PMCB Insider Trades
Joshua Silverman - OfficerOpen-market purchase$23K
Joshua Silverman - OfficerJoshua Silverman - OfficerJoshua Silverman - Officer
Wayne Remell Walker - Director
Michael M. Abecassis - DirectorPharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Other acquisition / disposition | 4 | 0 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
15 Form 4 filings on record, the earliest from Dec 12, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Wayne Remell Walker - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Michael M. Abecassis - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Jonathan Schechter - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Robert Weinstein - Director | Other | Stock Option (Right to Buy) | 0 | - | - | |
| Robert Weinstein - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Wayne Remell Walker - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Jonathan Schechter - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Michael M. Abecassis - Director | Grant or award | Stock Option (Right to Buy) | 119,170 | $0.00 | - | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 30,000 | $0.78 | $23K | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 30,000 | $0.79 | $24K | |
| Joshua Silverman - Officer | Open-market purchase | Common Stock | 40,000 | $0.83 | $33K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.78 | $16K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.79 | $16K | |
| Jonathan Schechter - Director | Open-market purchase | Common Stock | 20,000 | $0.84 | $17K | |
| Robert Weinstein - Director | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Robert Weinstein - Director | Tax withholding / forfeiture | Common Stock | 33,750 | $1.02 | $34K | |
| Robert Weinstein - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Wayne Remell Walker - Director | Grant or award | Common Stock | 37,500 | $0.00 | - | |
| Wayne Remell Walker - Director | Tax withholding / forfeiture | Common Stock | 16,875 | $1.02 | $17K | |
| Wayne Remell Walker - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Joshua Silverman - Officer | Grant or award | Common Stock | 575,000 | $0.00 | - | |
| Joshua Silverman - Officer | Tax withholding / forfeiture | Common Stock | 258,750 | $1.02 | $264K | |
| Jonathan Schechter - Director | Grant or award | Common Stock | 150,000 | $0.00 | - | |
| Jonathan Schechter - Director | Tax withholding / forfeiture | Common Stock | 67,500 | $1.02 | $69K | |
| Jonathan Schechter - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - | |
| Michael M. Abecassis - Director | Grant or award | Common Stock | 37,500 | $0.00 | - | |
| Michael M. Abecassis - Director | Tax withholding / forfeiture | Common Stock | 16,875 | $1.02 | $17K | |
| Michael M. Abecassis - Director | Grant or award | Stock Option (Right to Buy) | 63,233 | $0.00 | - |
PharmaCyte Biotech, Inc. (PMCB) had 4 insider filings in the last 90 days, with the most recent on 2026-07-17. The full record for PMCB runs to 15 Form 4 filings, the earliest from 2025-12-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of PMCB were filed in the last 90 days. 6 purchases are on record for this company.
No insider sales of PMCB were filed in the last 90 days.
This page tracks PMCB Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add PMCB to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
$PMDPSYCHEMEDICS CORP
$PMECPrimech Holdings Ltd
$PMFPIMCO MUNICIPAL INCOME FUND
$PMFLXPIMCO Flexible Municipal Income Fund
$PMIPicard Medical, Inc.
$PMLPIMCO MUNICIPAL INCOME FUND II
$PMMPUTNAM MANAGED MUNICIPAL INCOME TRUST
$PMOPUTNAM MUNICIPAL OPPORTUNITIES TRUST
$PMPEXPrimark Meketa Private Equity Investments Fund
$PMXPIMCO MUNICIPAL INCOME FUND IIIEvery Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.